Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?

view original post

So, Regeneron’s revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million and my ‘best case’ scenario by $55 million. Its non-GAAP EPS was $11.83, …